October 08, 2020
Article
In the metastatic breast cancer sphere, 2 chemotherapy agents have come to the forefront: capecitabine, for metastatic breast cancer, and eribulin, for triple-negative breast cancer.
October 07, 2020
Article
Treatment options for triple-negative breast cancer are historically limited; however, recent developments regarding the use of targeted therapies and various combination regimens have broadened the treatment spectrum and ushered in new clinical approaches.
September 17, 2020
Video
Joseph Gligorov, MD, PhD, discusses potential challenges of utilizing PARP inhibitors in triple-negative breast cancer.
September 17, 2020
Video
John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
September 17, 2020
Video
Adam M. Brufsky, MD, PhD, discusses the future role of chemotherapy in triple-negative breast cancer.